FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, namely to neurology and toxicology, and concerns treatment of neurological diseases using metalloporphyrins. For this purpose, an effective amount of AEOL10150 compound is introduced.
EFFECT: reduced brain damage when exposed to chemical toxic agents by reducing oxidative stress and mitochondrial dysfunction in brain cells.
22 cl, 7 ex, 17 dwg, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| AMYLOID-BINDING AGENTS | 2010 |
|
RU2517174C2 |
| CFTR REGULATORS AND METHODS FOR USE THEREOF | 2016 |
|
RU2742934C2 |
| CFTR REGULATORS AND THEIR APPLICATION METHODS | 2016 |
|
RU2749834C2 |
| CFTR REGULATORS AND METHODS OF USING | 2016 |
|
RU2730855C2 |
| OPHTHALMIC PHARMACEUTICAL COMPOSITIONS | 2018 |
|
RU2818087C2 |
| METHOD OF TREATING DISORDERS ASSOCIATED WITH ALKYLATING AGENT EXPOSURE | 2009 |
|
RU2506083C2 |
| MACROCYCLIC COMPOUNDS, APPLIED AS HISTONE DEACETYLASE INHIBITORS | 2011 |
|
RU2565076C2 |
| PROSTATIC SPECIFIC MEMBRANE ANTIGEN-TARGETED HIGH-AFFINITY AGENTS FOR PROSTATE CANCER ENDORADIOTHERAPY | 2017 |
|
RU2749399C2 |
| ESTERS OF BETA-HYDROXYBUTYRATE AND BUTANEDIOL FORMED BY MEDIUM-CHAIN FATTY ACIDS AND COMPOSITIONS AND METHODS BASED ON THEM | 2017 |
|
RU2761829C2 |
| SOME CHEMICAL STRUCTURES, COMPOSITIONS AND METHODS | 2009 |
|
RU2513636C2 |
